Repligen beats estimates as bioprocessing recovery gains traction
Repligen (NASDAQ:RGEN) reported fourth-quarter results that surpassed analyst forecasts, providing fresh evidence that the bioprocessing industry is successfully moving past its post-pandemic destocking phase.
The company posted quarterly revenue of $197.9 million, an 18% increase year-over-year, beating the consensus estimate of $192.2 million.
Growth was led by the Analytics and Proteins franchises, which helped drive a 14% increase in organic revenue.
Net income for the period reached $13.3 million, or $0.23 per share.
On an adjusted basis, earnings were $0.49 per share, comfortably ahead of the $0.44 per share anticipated by analysts.
For the full year 2025, Repligen generated $738.3 million in revenue and $48.9 million in net income.
Despite the quarterly beat, Repligen issued a 2026 profit forecast that fell slightly short of market expectations.
The company projected full-year adjusted earnings between $1.93 and $2.01 per share, compared to a consensus estimate of $2.07.
Revenue for 2026 is expected to range from $810 million to $840 million, representing reported growth of 10% to 14%.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
